Prioritization of PC14586 development and focused discovery research efforts results in a workforce reduction of approximately 30%Unaudited cash, cash equivalents, and marketable securities totaling approximately $229 million as of December 31, 2023, combined with cost savings from workforce reduction, is expected to extend cash runway to end of 2026PC14586 registrational Phase 2 clinical trial remains on track to initiate in 1Q24 PRINCETON, N.J., Jan.

PC14586开发和重点发现研究工作的优先次序导致截至2023年12月31日，未经审计的现金、现金等价物和有价证券的劳动力减少约30%，总计约2.29亿美元，再加上劳动力减少带来的成本节约，预计将现金跑道延长至2026PC14586年底注册第二阶段临床试验仍将按计划于2014年1月1日在新泽西州普林斯顿启动。

18, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor agnostic therapies targeting p53, today announced a strategic reduction of its workforce by approximately 30%. PMV will maintain a focused discovery research effort and expects that the resulting savings in operating expenses will extend its cash runway to the end of 2026.

182024年（环球通讯社）--PMV Pharmaceuticals，Inc.（纳斯达克：PMVP）是一家精密肿瘤学公司，率先发现和开发针对p53的小分子肿瘤不可知疗法，今天宣布将其劳动力战略性减少约30%。PMV将保持专注的发现研究工作，并预计由此节省的运营费用将延长其现金跑道至2026年底。

As of December 31, 2023, on an unaudited basis, PMV had approximately $229 million in cash, cash equivalents, and marketable securities. PMV estimates that it will incur aggregate charges of approximately $1.4 million, primarily for one-time employee severance and benefit costs, the majority of which are expected to be incurred in the first quarter of 2024.

截至2023年12月31日，在未经审计的基础上，PMV拥有约2.29亿美元的现金、现金等价物和有价证券。PMV估计，它将产生约140万美元的总费用，主要用于一次性员工遣散费和福利费，其中大部分预计将在2024年第一季度产生。

'I would like to express my sincere thanks to our employees impacted by this decision,” said David Mack Ph.D., PMV Pharma’s CEO and Co-founder. “We are grateful for their dedication and contributions to help bring PMV and PC14586 to this point of development. This is a difficult but necessary step to ensure that PC14586 is developed as efficiently as possible to benefit patients.” About PMV Pharma PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p5.

PMV Pharma首席执行官兼联合创始人David Mack博士说：“我要向受到这一决定影响的员工表示衷心的感谢。”。“我们感谢他们的奉献和贡献，帮助将PMV和PC14586带到这一发展点。这是确保PC14586尽可能有效地开发以造福患者的困难但必要的一步。”关于PMV Pharma PMV Pharma是一家开创小分子发现和开发的精密肿瘤学公司，针对p5的肿瘤不可知疗法。